Search

Displaying results 4381 - 4390 of 9670 in total
  1. Drug

    AP1081

    go.drugbank.com/drugs/DB05233
    Experimental

    A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.

  2. Drug

    Davamotecan pegadexamer

    go.drugbank.com/drugs/DB05899
    Investigational

    EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound camptothecin.

  3. Drug

    Felypressin

    go.drugbank.com/drugs/DB00093
    Investigational

    It is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth

  4. Drug

    Donislecel

    go.drugbank.com/drugs/DB17961
    Approved

    [L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196] … [L47166,L47196] The approval of donislecel was based on the safety and effectiveness evaluated in 2 clinical trials with 30 type 1 diabetic patients.

  5. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. … Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market.

  6. Drug

    Betameprodine

    go.drugbank.com/drugs/DB01552
    ExperimentalIllicit

    It exerts physiological effects characteristic of opioids, such as analgesia, euphoria and sedation, as well as itching, nausea, and respiratory depression. … The stereoisomer alphameprodine is similarly classified, and was more widely used (both are referred to as Meprodine). Betameprodine is a structural analogue of meperidine.

  7. Drug

    FRAX716

    go.drugbank.com/drugs/DB31795
    Experimental

    FRAX716 is a group I-specific p21-activated kinase (PAK) inhibitor which dramatically inhibits the phosphorylation of PAK and Mek1.[A274678]

  8. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.

  9. Drug

    Tocainide

    go.drugbank.com/drugs/DB01056
    ApprovedWithdrawn

    An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.

  10. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    such as gastrointestinal behavior, atopic dermatitis, psoriasis, skin inflammation, and COVID-19. … EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions